Accordingly, Khaw and colleagues showed venetoclax to be effective against only a minority of B-ALL xenografts in vivo, whereas combined BCL-2/BCL-xL inhibition resulted in synergistic killing in most models [47]. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.